Last reviewed · How we verify
BOTULINUM TOXIN TYPE B
Botulinum toxin type B blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type B blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | BOTULINUM TOXIN TYPE B |
|---|---|
| Also known as | MYOBLOC |
| Sponsor | Eisai Co., Ltd. |
| Drug class | Neurotoxin; botulinum toxin |
| Target | Synaptobrevin (VAMP) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin type B is a neurotoxin that cleaves synaptobrevin (VAMP), a protein essential for acetylcholine vesicle fusion and release at the neuromuscular junction. This prevents acetylcholine from being released into the synaptic cleft, resulting in temporary paralysis of the targeted muscle. The effect is reversible as the body gradually regenerates new SNARE proteins over several months.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Hyperhidrosis
- Migraine prophylaxis
- Spasticity
Common side effects
- Injection site pain or bruising
- Muscle weakness or paralysis (off-target)
- Headache
- Flu-like symptoms
- Antibody formation (neutralizing antibodies)
Key clinical trials
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (PHASE3)
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (PHASE3)
- Comparative Study Between Botulinum Toxin-A Injection and Shock Waves on Hypertrophic Scars in Hand-burned Children (NA)
- Repeated Botulinum Toxin Type A Injections on Intramuscular Fat Accumulation in Individuals With Sleep Bruxism. (NA)
- A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) (PHASE1)
- A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |